Revelation Biosciences, Inc. · NASDAQ:REVB
Revelation Biosciences — Investor Presentation (January 2022)
36 slides from Revelation Biosciences's investor presentation, Jan 13, 2022
Slide 1: Corporate Presentation January 2022
Developing innovative therapeutics and diagnostics to address unmet needs Corporate Presentation / January 2022
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation contains forward - looking statements as defined in the Private Securities Litigation Reform Act of 1995 , as amended . Forward - looking statements are statements that are not historical facts . These forward - looking statements are generally identifi
Slide 3: Development Pipeline
Development Pipeline 3 Pipeline consists of two therapeutic product candidates (REVTx - 99 and REVTx - 200) and one diagnostic product (REVDx - 501) Therapeutic Pipeline Discovery Preclinical Phase 1 Phase 2 Phase 3 Approval REVTx - 99 REVTx - 200 Diagnostic Pipeline Research Development Clinical Te
Slide 4: Project Milestones
Project Milestones Project Milestone Estimated Timing REVTx - 99: Nasal drops for the prevention and/or treatment of respiratory viral infection • Preclinical data (in vitro) for SARS - CoV - 2 and variants x Q1 2022 • Preclinical data (in vivo) for SARS - CoV - 2 and variants Q2 2022 • Phase 2 infl
Slide 5: Respiratory Viral Infections: A Perpetual Problem
Respiratory Viral Infections: A Perpetual Problem 5 Pathogen • Respiratory viruses enter through the nose and mouth, so how do you protect? • Masks and physical distancing offer only minimal protection • Vaccines offer good systemic protection, but effect is not immediate and they provide minimal mu
Slide 6: The Innate Immune Response
The Innate Immune Response 6 • The adaptive immune response results in the production of pathogen specific antibodies » The production of antibodies takes days to weeks to develop » Vaccines take advantage of the adaptive immune response Experienced Management and Scientific Team Pathogen » It works
Slide 7: The Importance of Cytokines and Innate Immunity
The Importance of Cytokines and Innate Immunity 4 Emerging Microbes and Infections, Dec 11, 2019 DOI: 10.1080/22221751.2019.1698271 5 Journal of Biological Chemistry, June 25, 2020 DOI: 10.1074/jbc.AC120.013788 6 Vaccine, April 2010, DOI:10.1016/j.vaccine.2010.03.062 7 Bio. Pharmacology Vol. 183, Ja
Slide 8: Intranasal solution for the Prevention of Respiratory Viral Infection
REVTx - 99 Intranasal solution for the Prevention of Respiratory Viral Infection
Slide 9: How it works
REVTx - 99: How it works • REVTx - 99 may be useful as a prophylaxis or early treatment for respiratory viral infections • REVTx - 99 activates the local innate immune response via stimulation of the TLR4 TRIF pathway causing: • REVTx - 99 • REVTx - 200 • REVDx - 501 9 • The protective cytokines act
Slide 10: Study Design and Clinical Data Supports Mechanism of Action
Study Design • Total number of subjects: 48 (6 cohorts, 8 subjects per cohort, 6 treated and 2 placebo) • Cohorts 1 - 5: treated group (N=6) receives a dose of either 5, 15, 30, 50 or 100 µg Cohort 6: 8 subjects. Each treated group will receive a dose of 100 µg daily x 5 • Readouts : Safety measurem
Slide 11: IP-10 as Key Cytokine
1 PLoS ONE, 2011 DOI:10.1371/journal.pone.0016333 2 PREP - 001 is a TLR - 3 agonist that demonstrated effectiveness in preventing both infection with rhinovirus and influenza in human clinical studies. The primary cytokine upregulated by PREP101 is IP - 10. IP - 10 was identified a priori as the key
Slide 12: Dose Dependent Increase in Intranasal IP-10
REVTx - 99 Produced a Dose Dependent Increase in Intranasal IP - 10 12 x REVTx - 99 stimulated an intranasal dose dependent response for IP - 10 in the Phase 1 clinical study Presented is a box and whisker plot of the fold - change values for all data and time - points including the mean fold - chan
Slide 13: Also Stimulated other Protective Cytokines
REVTx - 99 also Stimulated other Protective Cytokines MCP - 1 and IFN - ࢽ tracked with IP - 10 0 20 40 60 80 100 120 0 200 400 600 800 1000 1200 0 50 100 150 200 MCP - 1, IFN - g (pg/mL) IP10 (pg/mL) Time (hours) IP10-Right MCP1-Right IFN-g-Right 50 µg N: 11 Rate: 27% P: 0.05 0% 5% 10% 15% 20% 25% 3
Slide 14: Nonclinical Data Demonstrates Activity vs SARS-CoV-2 In Vitro
Nonclinical Data Demonstrates REVTx - 99 Activity vs SARS - CoV - 2 In Vitro x Additional testing ongoing including dose response, timing of dose and testing vs Omicron SARS - CoV - 2 Variant 0 0.5 1 1.5 2 2.5 3 3.5 Virus Control Pre-Treatment with REVTx-99 RAW SIGNAL (OPTICAL DENSITY) Human Primary
Slide 15: Preclinical Activity of PHAD in Mouse Model
Preclinical Activity of PHAD in Mouse Model 1 Trends in Microbiology, October 1, 2002, DOI: 10.1016/S0966 - 842X(02)02426 - 5 15 0 10 20 30 40 50 60 70 80 90 100 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Percent survival Days post influenza challenge PHAD (Day -2) PHAD (Day 0)
Slide 16: Phase 2 Viral Challenge Study
• Objective: To evaluate the efficacy of REVTx - 99 in reducing influenza virus load in the upper airways during infection • Primary Endpoint: Are a under the curve (AUC) of viral load by qPCR from nasal pharyngeal swabs • REVTx - 99 • REVDx - 200 • REVDx - 501 Next Step: Phase 2 Viral Challenge Stu
Slide 17: Market Need: Multiple Possible Uses
• REVTx - 99 • REVDx - 200 • REVDx - 501 Market Need: REVTx - 99 has Multiple Possible Uses with Potentially Large Markets 17 Seasonal virus prophylaxis (e.g. influenza season ) Seasonal Prophylaxis Potential Target Population At Risk Population. For example: • Health care workers • Elderly • Immuno
Slide 18: KOL Reactions
KOL Reactions to REVTx - 99 KOLs have favorable reactions to REVTx - 99 and were excited about its potential for use as a prevention for multiple types of viral infection 18 “It looks very compelling. It certainly addresses a lot of viral pathogens. The key one right now is COVID, but this potential
Slide 19: For the Treatment of Chronic Nasal Congestion
REVTx - 99 For the Treatment of Chronic Nasal Congestion
Slide 20: Rationale for Chronic Nasal Congestion: Eotaxin, Allergies and IP-10
Rationale for Chronic Nasal Congestion: Eotaxin, Allergies and REVTx - 99 • Eotaxin , an inflammatory cytokine, propagates allergies and inflammation through binding to the CCR3 receptor, which is expressed on a range of different cell types No REVTx - 99 With REVTx - 99 IP10 • REVTx - 99 • REVDx -
Slide 21: Phase 1b Nasal Challenge Study (RVL-CLR01)
Phase 1b Nasal Challenge Study (RVL - CLR01) Study Title: Effect of REVTx - 99 on Nasal Challenge with Allergen in Participants with Chronic Rhinosinusitis without Polyps Milestones • Enrollment up to 28 participants, randomized 1:1 across 4 cohorts • This will be a Phase 1b, randomized, double - bl
Slide 22: REVTx-200 Intranasal PHAD for Improved IM Vaccination
REVTx - 200 Intranasal PHAD ® for Improved Intramuscular (IM) Vaccination
Slide 23: REVTx-200 Overview
REVTx - 200 Overview • Development rationale » IM vaccination typically results in a robust immune response imparting systemic immunity, but elicitation of a weak mucosal response » REVTx - 200 stimulates the mucosal immune response to induce production of secretory IgA, cytokines, and chemokines, w
Slide 24: Strong Scientific Advisory Board Formed
Strong Scientific Advisory Board Formed Catherine Blish M.D., Ph.D. Dr. Blish is a Professor of Medicine and Immunology and the Associate Dean for Basic and Translational Research at the Stanford University School of Medicine . Her research is dedicated to learning how to harness the immune system t
Slide 25: Rapid testing kit for viral infection
REVDx - 501 Rapid testing kit for viral infection
Slide 26: REVDx-501: Broadly Applicable to Most Infectious Viruses
REVDx - 501: Broadly Applicable to Most Infectious Viruses • REVDx - 501 (REVID Œ ) is a diagnostic device in development for the detection of respiratory viral infection (SARS - CoV - 2, influenza A and B, parainfluenza, etc.) • REVDx - 501 detects IP - 10, a key cytokine that is upregulated in nas
Slide 27: A Universal Screening Tool
A Universal Screening Tool Current Testing Paradigm • REVID Rapid Screen allows for testing of large bodies of people because test: ▪ Works regardless of virus type and any viral variants ▪ Is rapid ▪ Is inexpensive REVID Œ Rapid Screen REVID Rapid Screen will allow large numbers of people to be scr
Slide 28: Market Need: Multiple Possible Uses
Market Need: REVDx - 501 has Multiple Possible Uses with Potentially Large Markets 28 The simplicity of the kit will allow individuals to make informed decisions on their general health and whether to quarantine or go about daily life Individual Screening Tool Potential Target Population General pop
Slide 29: Excellent Correlation between REVID and PCR for COVID
Excellent Correlation between REVID Œ and PCR for COVID COVID PCR Positive (N=37) COVID PCR Negative (N=153) REVID Positive 37 21 REVID Negative 0 132 • The results from the REVID Test Kit are in good agreement with PCR ▪ 0% false negative rate for replicating SARS - CoV - 2 virus ▪ 14% false positi
Slide 30: Management Leadership and Board of Directors
Management Leadership and Board of Directors
Slide 31: Board of Directors
Board – R&D Leadership, Therapeutic & Diagnostic Development, Commercialization, Finance and Transactional Success George Tidmarsh M.D., Ph.D. Chairman M.D. and Ph.D. from Stanford University. Currently Adjunct Faculty of Pediatrics and Neonatology. Over 30 years of experience in biotechnology, incl
Slide 32: Management has a Strong History Building Successful Commercial Organizations
Management has a Strong History Building Successful Commercial Organizations (e.g., 4 NASDAQ and 1 NYSE Listings) James Rolke Director and Chief Executive Officer Over 30 years of experience in the biotechnology industry. Chief Scientific Officer of La Jolla Pharmaceutical Company, development of mu
Slide 33: Key Takeaways
Key Takeaways 33 Revelation Portfolio Scientific Rationale Near Term Value Drivers Experienced Management and Scientific Team
Slide 34: Financial Overview
MS REVELATION BIOSCIENCES Financial Overview
Slide 35: Beneficial Holders and Cap Table
35 Beneficial holders Percent George Tidmarsh, M.D., Ph.D. 14.0% All other management 11.1% Total management 25.1% Petra Investment Holdings, LLC 13.7% AXA IM Prime Impact Fund 13.2% LifeSci Venture Partners II, LP & Affiliates 8.6% Monashee Investments 6.3% Meteora Capital Partners 5.8% Cap Table S
Slide 36: Thank you!
IVA REVELATION BIOSCIENCES Thank you!
Revelation Biosciences — Investor Presentation (January 2022) on 6ix